Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells

References

• Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510–517.
   PubMedGoogle Scholar
• Martelli AM, Evangelisti C, Chappell W, . Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011;25:1064–1079.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Peterson TR, Sabatini DM. Regulation of mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40:310–322.
   PubMed Web of Science ®Google Scholar
• Xu Q, Simpson SE, Scialla TJ, . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972–980.
   PubMed Web of Science ®Google Scholar
• Récher C, Beyne-Rauzy O, Demur C, . Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527–2534.
   PubMed Web of Science ®Google Scholar
• Tamburini J, Green AS, Bardet V, . Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009;114:1618–1627.
   PubMed Web of Science ®Google Scholar
• Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010;115:2127–2135.
   PubMed Web of Science ®Google Scholar
• Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009; 16:84–91.
   PubMed Web of Science ®Google Scholar
• Ketley NJ, Allen PD, Kelsey SM, . Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia 2000;14:620–628.
   PubMed Web of Science ®Google Scholar
• Trus MR, Yang L, Suarez Saiz F, . The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005;19:1161–1168.
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J, . Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 2009;125:1710–1720.
   Google Scholar
• Yang J, Ikezoe T, Nishioka C, . Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of AML cells in vitro and in vivo. Exp Hematol 2010;38:666–676.
   PubMed Web of Science ®Google Scholar
• Friend C, Scher W, Holland JG, . Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971; 68:378–382.
   PubMed Web of Science ®Google Scholar
• Monczak Y, Trudel M, Lamph WW, . Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. Blood 1997;90:3345–3355.
   PubMed Web of Science ®Google Scholar
• Kanayasu-Toyoda T, Yamaguchi T, Oshizawa T, . Role of the p70 S6 kinase cascade in neutrophilic differentiation and proliferation of HL-60 cells – a study of transferrin receptor-positive and -negative cells obtained from dimethyl sulfoxide- or retinoic acid-treated HL-60 cells. Arch Biochem Biophys 2002;405:21–31.
   PubMed Web of Science ®Google Scholar
• Vondráč ek J, Souc ek K, Sheard MA, . Dimethyl sulfoxide potentiates death receptor-mediated apoptosis in the human myeloid leukemia U937 cell line through enhancement of mitochondrial membrane depolarization. Leuk Res 2006;30:81–89.
   PubMed Web of Science ®Google Scholar
• Bruecher-Encke B, Griffin JD, Neel BG, . Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia 2001;15: 1424–1432.
   PubMed Web of Science ®Google Scholar
• Matkovic K, Brugnoli F, Bertagnolo V, . The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells. Leukemia 2006;20:941–951.
   PubMed Web of Science ®Google Scholar
• Mise J, Dembitz V, Banfic H, . Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells. Pathol Oncol Res 2011;17:645–656.
   PubMed Web of Science ®Google Scholar
• Wall M, Poortinga G, Hannan KM, . Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood 2008;112:2305–2317.
   PubMedGoogle Scholar
• Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T, . Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors. Exp Hematol 2001;29: 582–588.
   PubMed Web of Science ®Google Scholar
• Isakson P, Bjørås M, Bøe SO, . Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010;116:2324–2331.
   PubMed Web of Science ®Google Scholar
• Billottet C, Banerjee L, Vanhaesebroeck B, . Inibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting Atra-induced differentiation. Cancer Res 2009;69:1027–1036.
   PubMed Web of Science ®Google Scholar
• Gomez-Cambronero J, Frye T, Baumann M. Ribosomal p70S6K basal activity increases upon induction of differentiation of myelomonocytic leukemic cell lines HL60, AML14 and MPD. Leuk Res 2004; 28:755–762.
   PubMed Web of Science ®Google Scholar
• Lal L, Li Y, Smith J, . Activation of the p70S6K kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 2005;105;1669–1677.
   PubMed Web of Science ®Google Scholar
• Clarke CJ, Mediwala K, Jenkins RW, . Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase. J Biol Chem 2011;286:21565–21576.
   PubMed Web of Science ®Google Scholar
• Parmar S, Smith J, Sassano A, . Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005; 106:2436–2443.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zhang JW, Zhu HQ, . Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002;99:1014–1022.
   PubMed Web of Science ®Google Scholar
• Vondráček J, Sheard MA, Krejči P, . Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells. J Leukoc Biol 2001;69:794–802.
   PubMed Web of Science ®Google Scholar
• Hu Y, Yao J, Liu Z, . Akt phosphorylates acinus and inhibits its proteolytic cleavage, preventing chromatin condensation. EMBO J 2005;24:3543–3554.
   PubMed Web of Science ®Google Scholar
• Neri LM, Marchisio M, Colamussi ML, . Monocytic differentiation of HL-60 cells is characterized by the nuclear translocation of phosphatidylinositol 3-kinase and of definite phosphatidylinositol-specific phospholipase C isoforms. Biochem Biophys Res Commun 1999;259:314–320.
   PubMed Web of Science ®Google Scholar